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Abstract
Rationale/objectives There is a high prevalence of sub-
stance use disorder (SUD) in first-episode schizophrenia
(SZ), but its contribution to the underlying SZ pathophys-
iology remains unclear. Several studies using transcranial
magnetic stimulation (TMS) have observed abnormalities
in human motor cortex (M1) excitability in SZ. Studies on
cortical excitability comparing SZ patients with and without
comorbid substance abuse are lacking.
Methods A total of 29 first-episode SZ patients participated
in this study; 12 had a history of comorbid cannabis abuse
(SZ-SUD) and 17 did not (SZ-NSUD). We applied TMS to
right and left M1 areas to assess the resting motor threshold
(RMT), short-interval cortical inhibition (SICI), intracort-
ical facilitation (ICF), and the contralateral cortical silent
period (CSP).
Results In SICI and ICF conditions, right M1 stimulation
led to significantly higher motor evoked potential ratios in
SZ-SUD compared to SZ-NSUD. This suggests lower
cortical inhibition and increased ICF in first-episode SZ
with previous cannabis abuse. There were no group differ-
ences in RMT and CSP duration. Neither were there any
significant correlations between psychopathology (as
indexed by Positive and Negative Syndrome Scale), disease
characteristics, the extent of cannabis abuse, and TMS
parameters (SICI, ICF, and CSP).
Conclusions Comorbid cannabis abuse may potentiate
the reduced intracortical inhibition and enhanced ICF
observed in first-episode SZ patients in some previous
studies. This finding suggests an increased alteration of
GABAA and NMDA receptor activity in cannabis-abusing
first-episode patients as compared to schizophrenia
patients with no history of substance abuse. This may
constitute a distinct vulnerability factor in this special
population.
Keywords Schizophrenia.Substanceabuse.
Corticalinhibition.Transcranialmagneticstimulation
(TMS).Cannabinoids.Electrophysiology
Introduction
Substance abuse is common in patients with schizophrenia.
Various studies have reported prevalence rates for this
psychiatric comorbidity ranging from 15% to 65%, with
nicotine, alcohol, and cannabis as the most frequently
consumed substances (Cantor-Graae et al. 2001; Mueser et
al. 1990; Wobrock and Soyka 2008). In particular, cross-
sectional studies have found that cannabis abuse is
associated with an earlier onset of schizophrenia, and
longitudinal birth cohort studies have suggested that
cannabis abuse is an independent risk factor for the
development of schizophrenia (Semple et al. 2005;
Wobrock et al. 2007a).
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DOI 10.1007/s00213-009-1736-8Although it has been demonstrated that cannabis can
induce dopamine release (Voruganti et al. 2001)—and
increased dopaminergic transmission is seen in schizophrenia
(Abi-Dargham et al. 2000)—the understanding of the effects
of cannabis consumption on the pathophysiology of schizo-
phrenia and the neurobiological interaction between these
two conditions is far from complete (Rathbone et al. 2008).
In recent years, some evidence has accrued that alterations in
the endogenous cannabinoid system are linked to schizo-
phrenia. First, an association between a cannabinoid 1
receptor (CB1R) polymorphism and hebephrenic schizophre-
nia was observed (Ujike et al. 2002); second, the expression
of CB1Rs in the brain of schizophrenia patients was found to
be abnormal (Dean et al. 2001; Eggan et al. 2008); and third,
the level of endocannabinoid anandamide was significantly
elevated in the cerebrospinal fluid of antipsychotic-naive
first-episode paranoid-type schizophrenia patients relative to
healthy controls, affective disorder, and dementia patients
(Giuffrida et al. 2004).
Animal studies have provided evidence for a link between
GABAergic transmission and the cannabinoid system. Exog-
enous and endogenous cannabinoids take effect via CB1Rs
and may influence GABAergic transmission in various
cortical and subcortical brain areas (Hoffman and Lupica
2000, 2001;K a t o n ae ta l .1999, 2000).
Fittingly, some neurophysiological studies have reported
disturbances of GABAergic transmission in schizophrenia
patients. These studies have used paired-pulse transcranial
magnetic stimulation (TMS; Kujirai et al. 1993) to assess
mechanisms of Short-interval intracortical inhibition (SICI)
and intracortical facilitation (ICF). There is strong evidence
that SICI is mediated by GABAergic interneurons via
GABAA receptors, and that ICF results from prevailing
glutamatergic and weakened GABAergic interneuronal
influence (Ziemann 2004). For the detection of GABAB-
mediated cortical inhibition, the TMS measurement of the
contralateral cortical silent period (CSP) seems to be a
useful tool (Siebner et al. 1998; Werhahn et al. 1999).
Despite some controversy, a number of TMS studies have
linked schizophrenia to distinct abnormalities of cortical
excitability in the motoneural system. This research is
mainly pointing toward a GABAergic dysfunction in
schizophrenia (Daskalakis et al. 2002; Eichhammer et al.
2004; Fitzgerald et al. 2002a,b,c; Pascual-Leone et al. 2002;
Wobrock et al. 2008). Another important study has found
GABA-related transcripts in four cortical areas (dorsolateral
prefrontal cortex, anterior cingulate cortex, and primary
motor and primary visual cortices) to be lower in subjects
with schizophrenia (Hashimoto et al. 2008).
However, beyond this, the neurophysiological impact of
comorbid cannabis abuse in patients with schizophrenia is
largely unknown. Various studies have revealed a reduction
of event-related potentials—such as the auditory evoked
P300—both in schizophrenia, including its prodrominal
states, and after cannabis use (Coburn et al. 1998;
Frommann et al. 2008; Ozgürdal et al. 2008; Roser et al.
2008). These findings can be taken to reflect reduced
inhibition in cortico-subcortical loops, which in turn is
suggestive of GABAergic dysfunction.
In the present study, first-episode schizophrenia patients
with minimal exposure to antipsychotics were assessed with
single and paired-pulse TMS measuring SICI, ICF, and
CSP. While reduced SICI has already been demonstrated in
this patient sample relative to healthy control subjects
(Wobrock et al. 2008), the aim of the present study was to
compare motoneural cortical excitability between first-
episode schizophrenia patients with and without a history
of cannabis abuse. One recently published study found a
reduction of SICI in chronic cannabis abusers that might be
related to disturbances in GABAA transmission (Fitzgerald
et al. 2009). The literature discussed above likewise
suggests an alteration of GABAergic neurotransmission in
cannabis-abusing subjects. We therefore hypothesized that
comorbid schizophrenia patients would present with pro-
nounced disturbances in cortical inhibition relative to
patients without accompanying substance (cannabis) use
disorder (SUD).
Methods
Subjects
Twenty-nine patients with first-episode schizophrenia (all
paranoid subtype) participated in the study. They were
recruited from the Saarland University Hospital between
2003 and 2006. Exclusion criteria included a history of
dementia, neurological illness, severe brain injury or brain
tumors, abuse of substances other than cannabis, including
alcohol, or other contraindication to TMS. Each subject
underwent a detailed biographic interview (Bassett et al.
1993), a standardized test of hand preference (Annett 1970),
assessment of psychopathology (Positive and Negative
Syndrome Scale; Kay et al. 1987), an assessment of disease
severity (Clinical Global Impressions; Guy and Bonato
1976), and an assessment of social functioning (Global
Assessment of Functioning; Endicott et al. 1976). The
diagnosis was based on a consensus of two independent
psychiatrists performing the Structured Clinical Interview for
DSM-IV (SCID) I and II interviews (Fydrich et al. 1997;
Wittchen et al. 1997). Additionally, the duration of illness
(DUI; counted from the beginning of initial prodromal
symptoms), the duration of psychosis (DUP; counted from
the onset of diagnostic/characteristic positive symptoms),
and familial risk factors (psychosis in first-degree relatives)
were assessed.
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were assessed by the German version of the European
Addiction Severity Index (EuropASI), a standardized
clinical interview demonstrating high reliability and validity
in patients with alcohol and drug dependence (Scheurich et
al. 2000). Based on EuropASI and DSM-IV criteria of
substance abuse/dependence, we divided our patient sample
into two groups: Seventeen schizophrenia patients had no
lifetime history of substance use disorder (SZ-NSUD; five
of these had used cannabis up to five times in their
lifetime), and 12 patients had accompanying substance use
disorder (SZ-SUD; all cannabis use for more than 20 times
in their lifetime, at least weekly consumption over a period
of at least 12 weeks in the last 12 months; seven of these
patients had additionally used amphetamines occasionally
in their lifetime, but not in the last 3 months).
All 29 schizophrenia patients were treated with second
generation antipsychotics (aripiprazole, two; olanzapine,
18; quetiapine, two; risperidone, seven; and two patients
additionally treated with haloperidol). Yet, at the time of the
study, no patient had been treated longer than 6 weeks
continuously. To compare the cumulative and daily doses of
the different antipsychotics and to explore the influence of
this medication on TMS parameters, chlorpromazine (CPZ)
equivalents were calculated (as suggested by reviews and
studies focusing on second generation antipsychotics, e.g.,
Woods 2003). Sociodemographic and disease character-
istics as well as cumulative and daily doses of antipsychotic
medication (expressed in CPZ equivalents) are given in
Table 1.
There was no concomitant treatment with benzodiaze-
pines, mood stabilizers, beta-blocking agents, or anticholi-
nergics in the week before TMS measurement, and no
substance abuse in the 4 weeks before TMS measurement.
All participants had negative quantitative urine drug screens
for alcohol, tetrahydrocannabinol, amphetamines, halluci-
nogens, opiates, and their metabolites at the time of TMS
assessment. The patients did not display any signs of
withdrawal in the 4 weeks before and at the time of TMS
assessment. After a complete description of the study,
written informed consent was obtained from each subject.
The protocol was in accordance with the Declaration of
Helsinki and approved by the local ethics committee.
TMS procedure
Subjects were seated in a comfortable chair with their arms
supported passively. Electromyographic (EMG) recordings
from the right and left first dorsal interosseus muscle (FDI)
were made with surface electrodes, using a commercial
amplifier with a bandpass filter of 2 Hz to 10 kHz
(Keypoint portable, Medtronic Co., Denmark). Each signal
Table 1 Sociodemographic and clinical parameters of subgroups
SZ-NSUD (N=17) SZ-SUD (N=12) ANOVA
a
M SD M SD χ
2 Fd f p value
Age (years) 33.6 7.6 24.4 6.6 11.29 1, 27 0.002
Education (years) 11.3 1.7 9.8 1.5 5.69 1, 27 0.024
DUP (weeks) 61.9 76.9 50.4 64.0 1.35 1, 27 0.26
DUI (weeks) 213.9 184.3 139.7 99.6 1.60 1, 27 0.22
PANSS total score 93.1 13.5 96.7 20.5 0.33 1, 27 0.57
PANSS positive score 21.5 4.8 25.6 8.2 2.83 1, 27 0.10
PANSS negative score 22.2 5.9 21.5 7.1 0.08 1, 27 0.78
PANSS gen. psychop. score 49.4 7.8 49.6 11.4 0.00 1, 27 0.95
CGI 5.9 0.5 6.1 0.8 0.73 1, 27 0.40
GAF 28.8 8.3 28.3 13.1 0.01 1, 27 0.91
Daily dose of antipsychotics (CPZ-eq.) 295.9 176.4 441.7 216.2 3.99 1, 27 0.06
Cumulative dose of antipsychotics (CPZ-eq.) 6881.8 8536.4 8533.3 7112.8 0.30 1, 27 0.59
Gender (male/female)
b 11/6 10/2 1.22 1 0.27
Handedness (right/left/both)
b 17/0/0 8/0/4 6.57 1 0.010
SZ-NSUD schizophrenia patients without cannabis abuse, SZ-SUD schizophrenia patients with cannabis abuse, N number of patients, M mean, SD
standard deviation, DUP duration of psychosis, DUI duration of illness (including initial prodrome), PANSS Positive and Negative Syndrome
Scale, gen. psychop. general psychopathology, CGI Clinical Global Impressions, GAF Global Assessment of Functioning, CPZ-eq.
chlorpromazine equivalents, df degrees of freedom, FFstatistics, p probability
aAnalysis of variance (ANOVA)
bChi-square test
Psychopharmacology (2010) 208:353–363 355curve was manually analyzed offline. Focal TMS was
applied to the hand area of the left and right motor cortex
(allowing for the investigation of laterality differences)
using a figure-of-eight magnetic coil and a MagPro X 100
magnetic stimulator (Medtronic Co., Denmark).
The optimal coil positions were determined for each
subject individually. The optimal coil position was defined
as the stimulation site that produced the largest motor
evoked potential (MEP) in the resting right and left FDI
muscle, respectively, at moderately suprathreshold stimula-
tion intensities (i.e., intensities that induce MEPs of about
0.5–1.5 mV, SI1mV). Sites were marked to ensure constant
coil position throughout the experiment. The coil was held
tangentially to the head, with the handle pointing back-
wards and away from the midline at a 45° lateral angle.
This ensured that the induced current pointed forwards and
perpendicular to the central sulcus, which is optimal for
producing transsynaptic activation of corticospinal neurons.
The resting motor threshold (RMT), expressed as a
percentage of maximum stimulator output, was defined as
the lowest intensity that produced an MEP of >50 µV in at
least five out of ten trials in the relaxed FDI (Ziemann et al.
1996a).
SICI and ICF were assessed using standard paired-pulse
procedures (e.g., Eichhammer et al. 2004; Maeda and
Pascual-Leone 2003). The intensity of the first (condition-
ing) stimulus was always set to 80% of the RMT. The
second (test) stimulus was delivered at an intensity that
produced MEPs averaging 0.5–1.5 mV in the resting FDI
(SI1mV). Based on previous research showing that short
inter-stimulus intervals (ISIs) of 2–5 ms lead to inhibition
and longer ISIs (7–20 ms) lead to facilitation of test
stimulus MEPs (Kujirai et al. 1993), we used an ISI of 3 ms
in the inhibitory (SICI) and an ISI of 15 ms in the
facilitatory (ICF) paired-pulse TMS paradigm. We per-
formed a minimum of ten paired-pulse trials at each ISI and
at least tne single-pulse trials with an unconditioned test
stimulus. The effect of the conditioning stimulus on MEP
amplitude of the test stimulus was determined as the ratio of
the average amplitude of the conditioned test MEP (cMEP)
to the average amplitude of the unconditioned test MEP
(uMEP).
Measurement of the CSP duration was obtained with
moderately tonically active FDI (25–30% of maximal
contraction) by stimulating the contralateral motor cortex
with intensities of 120%, 140%, 160%, and 180% of RMT.
For each intensity, 16 trials were performed and the mean
CSP duration calculated. The CSP duration was defined as
the time from MEP onset to the return of voluntary EMG
activity (absolute CSP; Daskalakis et al. 2003).
The measurements were performed by an experienced
investigator, controlled by another experienced investigator,
and corrected for outliers and extreme values. Trials were
ordered quasi-randomly for each subject, and the order was
counterbalanced across groups. The investigator analyzing
the data was blinded to group status.
Statistics
Forstatisticalanalyses, SPSS for Windows 15.0was used. All
tests weretwo-tailed. Level ofsignificancewas set atα=0.05.
Dependent variables were RMT, SICI (ISI 3 ms), ICF (ISI
15 ms), and contralateral CSP (intensities 120%, 140%,
160%, and 180% of RMT) of both hemispheres. The
independent variable was SUD diagnosis (SZ-SUD and
SZ-NSUD).
One-way analysis of variance (ANOVA) and chi-squared
tests of independence were used to analyze differences
between the two diagnostic groups on demographic
variables age, education level, gender, and dexterity, as
well as clinical measures.
The primary analyses focused on SUD-group differences
in TMS measures. After applying Kolmogorov–Smirnov
tests and confirming normal distribution for RMT and CSP
variables, analysis of covariance (ANCOVA; with interven-
ing variables gender, hand preference, age, education level,
and CPZ equivalents) was used to test for significant
differences in CSP duration and RMT intensities between
the diagnostic groups. As the normality assumption was
violated for SICI and ICF, non-parametric tests (Mann–
Whitney U tests) were performed for these variables.
Laterality effects were assessed as follows. For RMT, a
repeated measures MANOVA (within-subject factor hemi-
sphere,between-subjectfactorSUDdiagnosis)wasperformed
to test the hypothesis that in right-handed subjects RMT is
lower in the left versus right motor cortex. The Wilcoxon rank
testwasusedtodetectdifferencesbetweenSICI/ICFmeasures
after left and right hemispheric stimulation.
Finally, Spearman rank correlations between SICI/ICF
variables and CPZ equivalents, total Positive and Negative
Syndrome Scale (PANSS), Global Assessment of Func-
tioning (GAF), Clinical Global Impression (CGI), DUP, and
DUI scores were computed across groups and for each
group separately.
Results
Sociodemographic and clinical characteristics
SZ-SUD subjects were significantly younger than SZ-
NSUD subjects (mean age, 24.4±6.6 years versus 33.6±
7.6 years, p=0.002). They also had a significantly lower
education level (9.8±1.5 versus 11.3±1.7 years, p=0.024).
The proportion of male patients was significantly higher in
the SZ-SUD group (p=0.023). While all SZ-NSUD
356 Psychopharmacology (2010) 208:353–363subjects were right handed, four patients of the SZ-SUD
group were ambidexters.
The patients suffered from moderate to severe positive
and negative symptoms according to the PANSS, accom-
panied by a severe degree of illness (CGI) and severe
impairment of social functioning (GAF). There were no
group differences in psychopathology (PANSS), disease
severity (CGI), global functioning (GAF), DUI (prodrome),
or DUP (for details see Table 1).
No subject fulfilled the criteria for borderline or antisocial
personality disorder (according to the SCID II interview,
DSM-IV axis II, personality disorders), which include
abnormally high impulsivity, which in turn is potentially
linked to reduced inhibition processes. The dosage of daily
and cumulative antipsychotic medication before TMS assess-
ment (expressed in CPZ equivalents) did not differ signifi-
cantly between the two groups, despite a trend toward higher
daily dosage in the SZ-SUD group (441.67 versus 295.88; p=
0.06). Across groups, more severely ill patients received
higher medication dosages: the cumulative doses and total
PANSS scores correlated positively at a trend level (rho=
0.34, p=0.068), and the correlation of cumulative dosage
and CGI was significant (rho=0.65, p<0.0005).
Resting motor threshold
RMT in both hemispheres was lower in SZ-SUD (left
motor cortex, 44.91%; right motor cortex, 47.0%) com-
pared to SZ-NSUD subjects (left motor cortex, 48.18%;
right motor cortex, 49.06%), but this difference was not
significant (see Table 2). The repeated measures MANOVA
(within-subject factor hemisphere, between-subject factor
SUD diagnosis) revealed no significant hemisphere effects
and in particular no interaction; hence, there was no
evidence for RMT asymmetry between groups.
Short-interval intracortical inhibition and intracortical
facilitation
SZ-SUD patients showed a reduced SICI (ISI 3 ms; 65.3%
lower inhibition stimulating right motor cortex; 36.3%
lower inhibition after stimulation of the left motor cortex)
and increased ICF (ISI 15 ms; 81.3% increased facilitation
stimulating right motor cortex; 50.8% increased facilitation
after stimulation of the left motor cortex) as compared to
SZ-NSUD patients. The reduction of SICI (Z=−2.2, df=1,
p=0.026; Mann–Whitney U test) and the increase of ICF
(Z=−2.0, df=1,p=0.047; Mann–Whitney U test) were both
significant following right motor cortex stimulation (see
Table 2, Figs. 1 and 2). Reduction of SICI and increase of
ICF in SZ-SUD compared to SZ-NSUD patients were not
significant when stimulating the left primary motor cortex
(for details see Table 2).
Since there were significant differences in age, education,
and hand preference, and also a trend level difference in daily
dosage of antipsychotic medication, we performed an addi-
tionalANCOVA (factor SUDdiagnosis;intervening variables
gender,age,educationlevel,anddailydosageofantipsychotic
medication). This was to rule out the possibility that the
significant results of the non-parametric tests were due to
these subgroup differences. With this approach, again, there
was a significant reduction of SICI [F(1,19)=19.1, p<0.001]
and a significant increase of ICF [F(1,19)=12.2, p=0.003]in
SZ-SUD compared to SZ-NSUD subjects.
Neither in the total sample nor in the subgroups were
there any differences in SICI/ICF measures comparing left
and right hemispheric stimulation (Wilcoxon rank test).
Cortical silent period
Increased stimulation intensity (120%, 140%, 160%, and
180% RMT) resulted in longer CSP duration in both
groups, as expected. No significant group differences were
found in CSP after either right or left motor cortex
stimulation (ANCOVA; factor SUD diagnosis; intervening
variables gender, age, education level, hand preference, and
daily dosage of antipsychotic medication; for details see
Table 2).
Looking at overall hemispheric differences, CSP dura-
tion tended to be longer after right motor cortex stimulation
at 180% RMT intensity (left FDI; p=0.083, MANOVA,
within-subject factor hemisphere). Looking at hemispheric
difference effects between groups (effectively the hemi-
sphere × group interaction), the hemispheric CSP difference
(CSP left FDI–CSP right FDI) at 120% RMT stimulation
intensity was positive (left > right FDI) for SZ-NSUD and
negative (right > left FDI) for SZ-SUD patients. The
corresponding hemisphere by group ANOVA returned a
significant interaction effect [F(1,26)=4.10, p=0.054]. That
is, SZ-SUD patients displayed a slightly longer CSP after
left motor cortex stimulation (right FDI) and a shorter CSP
after right motor cortex stimulation (left FDI) than SZ-
NSUD patients. We also calculated a CSP duration
asymmetry index at 120% RMT [AI=2 (right − left) (right +
left)] and found this to be negative in SZ-NSUD patients
(−0.0568) and positive in SZ-SUD patients (+0.1849). This is
a significant difference [F(1,26)=4.28, p=0.049; ANOV A],
although it would not survive adjustment for multiple testing
(Bonferroni correction).
Influence of clinical variables and antipsychotic medication
on TMS parameters
To detect any influence of clinical variables or medication on
SICI/ICF, we calculated non-parametric correlations (Spear-
man rank correlations) between these variables and TMS
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thology (PANSS), disease severity (CGI), social functioning
(GAF), DUP, or DUI and TMS parameters (SICI, ICF, and
CSP) were observed. In addition, the duration of cannabis
abuse (weeks of consumption) and the age of cannabis abuse
onsetwerenotsignificantlycorrelatedwitheitherSICIorICF.
As outlined before, SZ-SUD patients tended to receive a
higher daily dose (CPZ equivalents) of antipsychotic medica-
tion than SZ-NSUD patients. While there was no significant
correlation between SICI and cumulative or daily dose of
antipsychotics, in the SZ-SUD group, there was trend-level
association between the cumulative antipsychotic dose and
ICF following right motor cortex stimulation (rho=0.517, p=
0.05) but not left motor cortex stimulation.
Discussion
The present study used TMS to investigate motor cortical
excitability in schizophrenia patients with and without
comorbid SUD (cannabis). The TMS technique allows
noninvasive testing of inhibitory and excitatory intracortical
networks in the human brain. In contrast to most animal
research, TMS can describe alterations at the system level
of the human cerebral cortex; this level typically has a
closer relation to the clinical context (Lang et al. 2008).
In a previous study, we were able to identify an SICI
reduction in a sample of first-episode schizophrenia patients
relative to healthy control subjects. This suggested that a
GABAergic deficit may be involved in schizophrenic
pathophysiology, which would support the functional
dysconnectivity hypothesis (Wobrock et al. 2008). Func-
tional disconnectivity in schizophrenia—as indexed by
TMS measures—has also been found between posterior
parietal cortex and ipsilateral motor cortex (Koch et al.
2008). To our knowledge, our study is the first to use TMS
to explore the effects of accompanying cannabis abuse on
cortical excitability in schizophrenia.
The main result of our study is that schizophrenia
patients with a history of cannabis abuse (SZ-SUD) showed
Table 2 Comparison of TMS parameters between subgroups
SZ-NSUD
(N=17)
SZ-SUD
(N=12)
ANCOVA
c Mann-Whitney
U-Test
M SD M SD df F p value df Z p value
RMT left motor cortex (%)
a 48.18 7.30 44.91 6.35 1, 19 0.26 0.62
RMT right motor cortex (%)
a 49.06 8.41 47.00 7.66 1, 19 0.35 0.56
ppTMS
SICI (ISI 3 ms) left motor cortex
(ratio cMEP/uMEP)
b
0.36 0.33 0.49 0.32 1 −1.5 0.14
SICI (ISI 3 ms) right motor cortex
(ratio cMEP/uMEP)
b
0.41 0.40 0.67 0.68 1 −2.2 0.026
ICF (ISI 15 ms) left motor cortex
(ratio cMEP/uMEP)
b
1.41 1.07 2.13 1.63 1 −1.6 0.13
ICF (ISI 15 ms) right motor cortex
(ratio cMEP/uMEP)
b
1.48 1.18 2.67 1.99 1 −2.0 0.047
Cortical silent period
CSP right FDI 120% RMT (ms) 159.81 48.81 169.91 23.63 1, 21 0.2 0.65
CSP right FDI 140% RMT (ms) 207.83 47.04 208.04 32.98 1, 19 0.3 0.60
CSP right FDI 160% RMT (ms) 235.27 40.85 237.75 31.24 1, 21 0.9 0.35
CSP right FDI 180% RMT (ms) 239.69 30.38 257.31 39.00 1, 16 1.6 0.22
CSP left FDI 120% RMT (ms) 171.84 59.68 145.05 43.77 1, 22 0.0 0.99
CSP left FDI 140% RMT (ms) 211.64 63.75 213.50 46.18 1, 19 0.7 0.42
CSP left FDI 160% RMT (ms) 240.61 51.10 246.27 41.45 1, 19 1.2 0.29
CSP left FDI 180% RMT (ms) 255.54 61.80 268.19 21.92 1, 16 0.1 0.93
SZ-NSUD schizophrenia patients without cannabis abuse, SZ-SUD schizophrenia patients with cannabis abuse, M mean, SD standard deviation, N
number of patients, df degrees of freedom, FFstatistics, p probability, ZZvalue, cMEP conditioned motor evoked potential, uMEP
unconditioned motor evoked potential, RMT resting motor threshold, ANCOVA analysis of covariance, CSP contralateral cortical silent period,
FDI first dorsal interosseus muscle, ms milliseconds
aPercentage of maximum stimulator output
bAs ppTMS variables were not normally distributed, non-parametric testing (Mann-Whitney U test) was used
cAge, education, and chlorpromazine-equivalents were included as covariates
358 Psychopharmacology (2010) 208:353–363a reduced GABAA-mediated SICI and an enhanced ICF
compared to patients with no cannabis abuse history (SZ-
NSUD). The GABAB-mediated CSP and parameters of
corticospinal excitability such as RMT and SI1mV did not
differ between the groups. We found no significant
hemispheric differences in TMS measures (after Bonferroni
correction).
In our study, SZ-SUD patients were significantly
younger and less educated than SZ-NSUD patients. This
is in accordance with other cross-sectional studies (Cantor-
Graae et al. 2001; Mueser et al. 1990; Wobrock and Soyka
2008); therefore, our patient samples seem to be represen-
tative for this special patient population. Importantly,
psychopathology and disease severity did not differ
between the two schizophrenia subgroups.
A number of TMS studies have now found reduced
intracortical inhibition and enhanced ICF in schizophrenia
patients (Daskalakis et al. 2002; Eichhammer et al. 2004;
Fitzgerald et al. 2002a,b,c; Pascual-Leone et al. 2002;
Wobrock et al. 2008). SICI seems to be induced by
GABAergic interneurons via α2- or α3-GABAA receptors
(Di Lazzaro et al. 2007; Siebner et al. 1998), whereas ICF
relates to the excitability of excitatory neuronal circuits in
motor cortex; these circuits are at least partially dissociable
from the SICI network (Ziemann 2004). In schizophrenia,
GABAergic dysfunction, decreased levels of the mRNA
expression of the GABA-synthesizing enzyme glutamic acid
decarboxylase (GAD67), and a reduction of GABAergic
interneurons are all observed (Benes 1998;K n a b l ee ta l .
2002; Lewis et al. 2005). Furthermore, expression levels of
seven GABA-related transcripts have been found to be
reduced in subjects with schizophrenia in four cortical regions
(includingthemotorcortex);thesechangesmaycausecortical
dysfunctioninschizophrenia patients(Hashimotoetal.2008).
These neuropathological and neurobiological findings
are in line with the reduced SICI observed in schizophrenia.
Our results most likely reflect an amplified GABAergic
deficit and a distinct functional intracortical disconnectivity
in cannabis-abusing schizophrenia patients. Our data
demonstrate, for the first time, the influence of previous
cannabis abuse on cortical GABAergic function in schizo-
phrenia patients.
The influence of cannabis consumption on TMS meas-
ures in subjects not suffering from schizophrenia was
investigated in a recently published study by Fitzgerald et
al. (2009). These authors examined 42 chronic cannabis
users (both heavy and light users) and observed reduced
SICI relative to healthy controls, without any differences in
CSP. This finding corroborates our view that chronic
cannabis use may cause a GABAA-mediated reduction of
intracortical inhibition without any influence on GABAB
activity.
In summary, there is convincing evidence for a link
between cannabis, schizophrenia, and the GABAergic
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Fig. 2 Intracortical facilitation (ICF) in the schizophrenia subgroups.
First-episode schizophrenia patients with comorbid cannabis abuse
(SZ-SUD) showed significantly enhanced facilitation (facilitatory ISI
of 15 ms; higher ratio, conditioned MEP/unconditioned MEP; mean,
95% CI) compared to patients without previous cannabis abuse (SZ-
NSUD) in right motor cortex (Z=−2.0, p=0.047; Mann–Whitney U
test). CI confidence interval, cMEP conditioned motor evoked
potential, uMEP unconditioned motor evoked potential, ISI interstim-
ulus interval, SZ-NSUD patients with first-episode schizophrenia
without previous cannabis abuse, SZ-SUD patients with first-episode
schizophrenia and comorbid cannabis abuse
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Fig. 1 Short interval cortical inhibition (SICI) in the schizophrenia
subgroups. First-episode schizophrenia patients with comorbid canna-
bis abuse (SZ-SUD) showed significantly reduced cortical inhibition
(SICI; inhibitory ISI of 3 ms; higher ratio, conditioned MEP/
unconditioned MEP; mean, 95% CI) compared to patients without
previous cannabis abuse (SZ-NSUD) in right motor cortex (Z=−2.2,
p=0.026; Mann–Whitney U test). CI confidence interval, cMEP
conditioned motor evoked potential, uMEP unconditioned motor
evoked potential, ISI interstimulus interval, SZ-NSUD patients with
first-episode schizophrenia without previous cannabis abuse, SZ-SUD
patients with first-episode schizophrenia and comorbid cannabis abuse
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reporting a reduction of event-related potentials—such as
the auditory evoked P50 or P300—in both schizophrenia,
including its prodrominal states, and after cannabis use
(Adler et al. 1982; Coburn et al. 1998; Frommann et al.
2008; Ozgürdal et al. 2008; Roser et al. 2008), probably
also reflecting reduced inhibition in a cortico-subcortical
loop.
The active compound of herbal cannabis, delta-9-
tetrahydrocannabinol (THC), exerts all of its known central
effects through CB1Rs. Cannabinoids, via CB1Rs, influ-
ence the release of glutamate, dopamine, acetylcholine, and
GABA primarily presynaptically. In contrast, the cellular
mechanisms involved in the inhibition of neurotransmitter
release by cannabinoids are still not fully understood
(Iversen 2003). Several mechanisms are suspected to be
engaged in these inhibitory effects of CB1R activation,
including activation of N-type Ca2
+ currents (Caulfield and
Brown 1992), a reduction of the frequency of Ca2
+-
independent excitatory or inhibitory synaptic currents
(Schlicker and Kathmann 2001), and decreased phosphor-
ylation of A-type K
+ channels by the cAMP-dependent
enzyme protein kinase A (Deadwyler et al. 1995). In the
rodent hippocampus, a specific class of GABAergic
interneurons was detected to express CB1Rs, and moreover,
endogenous and exogenous cannabinoids were shown to
inhibit GABA release in CA1 pyramidal cells (Hoffman
and Lupica 2000; Katona et al. 1999, 2000) and pyramidal
cells of the ventral tegmental area (Pistis et al. 2001).
In our study, patients with a double diagnosis showed an
enhanced ICF. Likewise, atropine, a cholinergic antagonist,
has been found to enhance ICF (Liepert et al. 2001), while
NMDA antagonists and chronic nicotine exposure have
been associated with an ICF reduction (Lang et al. 2008;
Schwenkreis et al. 1999; Ziemann et al. 1998). The
enhanced ICF in schizophrenia patients with comorbid
cannabis abuse might hence best be explained by an
increased glutamatergic input and reduced GABAAergic
neurotransmission, while a disturbance in cholinergic intra-
cortical neuronal circuits may also play a role.
Previous studies investigating the action of addictive
drugs (other than cannabis) on cortical excitability have
revealed partially conflicting results. Chronic nicotine
abuse, acute alcohol exposure, and alcohol dependence
have been associated with enhanced inhibition and reduced
facilitation in specific neuronal circuits in motor cortex
(Conte et al. 2007; Lang et al. 2008; Ziemann et al. 1996b).
Cocaine addicts showed decreased excitability of the motor
cortex (Boutros et al. 2005), whereas ecstasy users
demonstrated increased excitability of the visual cortex
(Oliveri and Calvo 2003). Apart from the specific type of
drug under investigation, there are two likely reasons why
the observed effects of drug modulation contrast with the
effects reported in the present study: First, effects may
critically depend on specific neurodevelopmental brain
abnormalities in schizophrenia patients (Falkai et al.
2008). Secondly, most of the TMS studies investigating
addictive drug effects on cortical excitability have looked at
acute drug effects or have tested subjects that were under
the influence of the drug at the time of TMS measurement.
In our sample, we assessed patients in a drug-free interval,
to investigate the pathophysiology of this double diagnosis
condition without the influence of acute drug effects or
long-lasting intoxication effects.
However, our study has several limitations. Although we
collecteddataabout the pattern ofsubstance abuse,wedid not
differentiate between different types of cannabis or the
average amount of cannabis per use. The content of
psychoactive THC varies widely across different types of
cannabis(Potteretal.2008). This complicates the exploration
of dose–response relationships, although in our sample, we
found no correlation between TMS parameters and the
amount of cannabis consumption (lifetime days of use).
Secondly, antipsychotic medication could be a consider-
able confounding factor in TMS paradigms (Davey et al.
1997). For instance, one study found a difference in RMT
between patients treated with risperidone (increased RMT)
and olanzapine (decreased RMT; Fitzgerald et al. 2002c).
For paired-pulse measurements, medication influencing
GABA, glutamate, serotonin, or dopamine transmission
could be potentially relevant because the interneuronal-
pyramidal circuits are mediated via these pathways.
However, according to the literature, one would expect that
antipsychotics should compensate for the reduced inhibition
or increased facilitation and should not produce it, as there
are no studies available showing increased cortical inhibi-
tion in medicated (or unmedicated) schizophrenia and only
one study demonstrating reduced cortical inhibition exclu-
sively in medicated patients (Pascual-Leone et al. 2002). In
our study, we could not rule out an influence of
antipsychotic dosing on ICF completely, as we detected a
positive correlation between the extent of facilitation (MEP
ratio) and the cumulative antipsychotic dosage in the SZ-
SUD patient group.
Furthermore, although we consider our patient sample to
be quite representative, groups differed in central demo-
graphic parameters (gender, age, and education). This may
have affected our main results, although we consider this
unlikely, as we adjusted our analyses for confounding
variables. Another limitation is that we did not determine
the concentration of endogenous cannabinoids (e.g., anan-
damide) in the CSF, as it has been done in previous studies
with cannabis abusing schizophrenia patients (Leweke et al.
2007). It would have been interesting to see if dysregula-
tions of the endogenous cannabinoid system contributed to
the observed GABAergic dysfunction as assessed by TMS.
360 Psychopharmacology (2010) 208:353–363Finally, we did not administer THC in a controlled
fashion and therefore cannot conclude directly that the
cortical excitability differences between the groups under
investigation were caused by cannabis consumption. Alter-
natively, the excitability differences could represent a kind
of brain dysfunction that precedes clinical diagnosis of
schizophrenia and increases the risk for SUDs. We do not
consider this alternative interpretation likely.
The strength of our study is that we were able to
investigate a sample of first-episode patients that was both
well-characterized and representative for this patient popu-
lation in a clinical setting. Due to disease severity and the
clinical necessity for medication, it was of course not
possible to test these patients in a neuroleptic-naive setting.
Summing up, this study affords novel insights into the
cortical physiology of schizophrenia patients with comorbid
cannabis use disorder. The etiological relationship between
the two diagnoses is not yet fully understood, but this study
supports the theory that cannabis abuse acts as a distinct
vulnerability factor for schizophrenia through an increase in
GABAergic dysfunction. Alternatively, our results support
the hypothesis of an increased sensitivity to the effects of
drugs in this special population.
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